Fermentation

Bee-free honey produced ex vivo by precision fermentation: recombinant bee enzymes (invertase, glucose oxidase) expressed in Pichia pastoris convert a blended plant-sugar and phytochemical base into a vegan, hypoallergenic honey chemically identical to the natural product.

Renewable routes to acrylic acid, the C3 monomer behind superabsorbent polymers, paints, coatings and adhesives, across two distinct value chains: bioethanol-derived bio-based acrylate esters already commercial at Arkema (Carling, France, bio-based ethyl acrylate at 40% bio carbon content since October 2024) and BASF (Ludwigshafen, portfolio switched to bio-based ethyl acrylate in August 2024), and direct fermentative acrylic-acid routes via 3-hydroxypropionic acid (Cargill's Issatchenkia orientalis SD108 platform) or direct yeast fermentation (Genomatica's Saccharomyces cerevisiae host at ~30 mg/L laboratory titre) still at pilot or research scale — no Chinese commercial originator confirmed as of 2026.

Bio-based plasticizers replace regulated petroleum-derived phthalates (DEHP, DBP, DINP — under EU REACH SVHC and US EPA scrutiny for endocrine-disrupting effects) with renewable alternatives: epoxidized soybean oil (ESO/ESBO, the leading non-phthalate at ~8.4% of China's plasticizer consumption), isosorbide diesters (from starch/sorbitol), citrate esters (ATBC, food-contact), cardanol-based (from cashew nutshell liquid), and mass-balance bio-attributed resins (ISCC PLUS). Arkema secured ISCC PLUS mass balance certification for its Pasir Gudang Malaysia resins plant (Feb 2025) and brought a $20M Rilsan® Clear transparent polyamide unit online in Singapore (Q1 2026, 45-62% bio-based carbon from castor oil); Lanxess launched a sustainable Mesamoll® version with bio-mass raw materials and presented Vulkanox 4060 (6PPD alternative) at Tire Technology Expo 2026 (Hannover, March). ESO/ESBO dominates on volume (Cargill US, VVF India, Shandong Longkou China), approved for food-contact PVC under FDA 21 CFR 178 and EU REACH.

Bio-derived solvents — ethyl lactate from fermented lactic acid (Corbion's Biviture brand, Galactic's Galactic bio-solvents line, Vertec Biosolvents' corn-based MEK-replacements now under Shrieve Chemical ownership) and bioethanol-derived ethyl acetate — replacing MEK, toluene and xylene in paints, coatings, industrial degreasing and pharma processing, alongside BASF's biomass-balanced BMBcert intermediates that attribute renewable carbon into existing solvent families via mass-balance accounting — a mature commercial niche with no dedicated Chinese or Indian originator confirmed as of 2026.

Microbial surface-active glycolipids (rhamnolipids, sophorolipids, MELs) produced by aerobic fermentation of plant oils and sugars — biodegradable, low-toxicity replacements for petrochemical surfactants in detergents, personal care, agchem and enhanced oil recovery.

Capsaicin — the pungent capsaicinoid of Capsicum peppers — is at the intersection of plant-cell biotechnology (Debut's cultivation-free fermentation), precision-fermentation flavour modulation (DSM-Firmenich, Givaudan) and a centuries-old capsicum-oleoresin extraction base anchored in India by Plant Lipids; fermentation-route biosynthesis remains emerging while extraction still dominates global supply.

Cocoa-price shocks (West African drought, CSSV crop disease, prices above $10,000/tonne) and the EU Deforestation Regulation have pulled real B2B capital into cocoa-free alternatives: Planet A Foods' oat/sunflower ChoViva now supplies Mars (May 2026 launch) and Lufthansa; Cargill distributes Voyage Foods' sunflower/grape-seed NextCoa across North America (also launched May 2026); WNWN Food Labs (UK) ferments barley and carob into its Waim! bars; and California Cultured's cell-cultured cocoa biomass remains pilot-scale, pending an FDA GRAS dossier. No Chinese commercial originator (Jiangnan University's cocoa-butter-equivalent yeast research, Bota Biosciences, Bluepha) cleared source confirmation as of 2026.

Bio-based platform chemicals — succinic acid, itaconic acid, FDCA, and 1,4-BDO — produced via precision fermentation from C5/C6 sugars, replacing fossil feedstocks for biopolymers, plastics, and specialty chemicals; $5B market in 2025, growing >15% CAGR to 2030.

Theobromine (3,7-dimethylxanthine) — cocoa's signature xanthine alkaloid — is sourced today from cocoa-processing byproducts (Cargill) and methylxanthine API manufacturing (Bajaj Healthcare, CSPC Innovation Pharma), while precision-fermentation and deforestation-free molecular synthesis (DSM-Firmenich, Fermtech) emerge under EU Deforestation Regulation pressure; this article covers the pure molecule, distinct from cocoa-free chocolate alternatives.

Brewing and distillation capacity (250–500 m³ tanks) is being repurposed as a fermentation CDMO platform for recombinant proteins — from beer and spirits to collagen and albumin.

Microbial food protein grown by feeding hydrogen-oxidising bacteria a mix of hydrogen, CO2 and oxygen in gas-loop bioreactors — a land-free 'food from air' route now at commercial demonstration scale.

Industrial enzymes and biocatalysis replace chemical processes with protein-catalyzed reactions — cutting energy by 40–70%, reagent costs, and waste streams across food, feed, pharma, textiles, and biofuels. The global market exceeds $7B with >6% CAGR through 2030.

Microbial single-cell protein grown by fermenting methane, CO2/hydrogen or side-streams into a high-protein feed ingredient that displaces fishmeal and deforestation-linked soymeal.

Fungal biomass protein (mycoprotein) and mycelium materials produced via fermentation of Fusarium, Neurospora and Trichoderma — a $4.6B market growing at 12% CAGR.

Genetically engineered microbes as cell factories for proteins, enzymes, HMOs and flavors — a stack from strain design to purified ingredient, at 30–50 g/L target titers.

Recombinant whey, casein and egg-white proteins produced by engineered yeast and filamentous fungi, cutting GHG emissions 90–97% and water use 95–99% versus animal farming.

Engineered yeast and fungi now express the bioactive milk proteins — above all lactoferrin, the iron-binding 'pink gold' that is just 1 percent of whey and historically over 650 US dollars a kilo — that close the gap between infant formula and breast milk, with the first US FDA GRAS no-questions letters (TurtleTree 2025, All G 2026) and the Nestlé-Helaina and Novonesis-TurtleTree partnerships moving precision-fermented ingredients from B2B supply into finished early-life nutrition.

Species-specific probiotics and heat-stable postbiotics for dog and cat gut health — a $3.2B market driven by pet humanisation, growing at 11% CAGR.

Recombinant and next-generation engineered botulinum neurotoxins (BoNT) — expressed via DNA technology or reformulated as complex-free / ready-to-use liquids — are displacing traditional Clostridium botulinum fermentation: AbbVie/Allergan's Boey® (trenibotulinumtoxinE, recombinant serotype E) won EU and Health Canada approval in 2026 with onset as early as 8 hours and a 2-3 week duration across 2,100+ Phase 3 patients; Galderma's Relfydess™ (relabotulinumtoxinA, PEARL™ Technology ready-to-use liquid) reached 33 markets including EU approval across 16 countries in 2026; Merz's Xeomin (incobotulinumtoxinA, complexing-protein-free naked toxin) holds 79-country approval; Eirion's AI-09 ready-to-use recombinant liquid injectable achieved 6-month duration at the highest dose in a 96-subject Phase 1-2 trial. China's Lanzhou/CNBG Hengli® (衡力) — the country's first domestic BoNT-A (2002 approval, 30+ years lineage) — leads the local market with first-in-China 2025-2026 approvals for axillary hyperhidrosis and benign masseter hypertrophy while domestic recombinant R&D remains pre-commercial.

Recombinant human serum albumin (rHSA) replaces plasma-derived HSA (pHSA) — constrained by donor blood supply and viral contamination risk since the 1940s — with biosynthetic production in yeast (Pichia pastoris, Hansenula polymorpha) or plant (rice endosperm) hosts: Healthgen Biotech's OsrHSA (奥福民®) became the world's first NMPA-approved rHSA injection (July 2025) with 1-million-vial annual capacity and a 22-centre Phase III in decompensated liver cirrhosis; InVitria's Exbumin (rice-derived, ExpressTec platform) is the excipient in Merck's ERVEBO Ebola vaccine — the first FDA/EMA/PMDA-approved rice rHSA in an injectable — and Optibumin 25 (launched April 2025) is the first recombinant 25% HSA for closed-system biomanufacturing; Proliant launched AlbufreeDX (June 24, 2026) for diagnostics; Basic Pharma (NL) + ARTES Biotechnology (DE) make Hansenula polymorpha rHSA; Shilpa Medicare's sRbumin® became India's first rHA Phase 1 completion (August 2024), with CDSCO Phase III nod (November 2024) and an Orion Europe commercialization deal. The global rHSA market stood at USD 166M in 2025, projected to USD 421M by 2035 (CAGR 9.75%).

Recombinant silk fibroin and spider-silk proteins — expressed via microbial precision fermentation (Spiber Brewed Protein™, AMSilk Biosteel, Bolt Threads MicroSilk), transgenic *Bombyx mori* silkworms (Kraig Biocraft MaSp1/MaSp2), or purified from *Bombyx mori* cocoons for biomaterials (Sofregen Medical SilkVoice FDA-cleared ENT device) — have crossed into commercial scale in 2026: Spiber's Rayong Thailand plant and 2025 Italian-mill partnerships (Botto Giuseppe, Manifattura Sesia, Achille Pinto) produced 100% Brewed Protein yarns at industrial tonnage; AMSilk's bioengineered yarns debuted in Balenciaga Spring 2026 collection and Ajinomoto Foods Europe's dedicated 160 m³ Nesle France fermentation plant came online July 2026; Kraig Biocraft hit 1.3 metric tons of recombinant spider silk cocoons in March 2026 (1.8 MT in April) via transgenic silkworms in Vietnam; Sofregen Medical's SilkVoice holds two FDA 510(k) clearances (K180631, K240919) for vocal cord medialization, validated in a 33-patient Laryngoscope 2026 study. Bolt Threads patented recombinant silk polypeptide as a silicone replacement in personal care (US20260069524A1, March 2026).